• ≥18 years at the time consent is signed.

• Ability to provide written informed consent for the study.

• ECOG PS of 0 or 1.

• Participants of childbearing potential must not be pregnant at enrollment and agree to comply with contraception requirements. Participants with partners of childbearing potential must also comply with contraception requirements.

• Adequate organ function as defined below. Specimens must be collected within seven days prior to the start of the study treatment (i.e., Cycle 1 Day 1 \[C1D1\])

• Life expectancy of ≥12 weeks, per treating investigator's judgment.

• For Melanoma participants: Participants with unresectable or metastatic melanoma that have progressed on or after PD 1/PD L1 checkpoint blockade (alone or with either CTLA 4 or LAG 3 checkpoint blockade).

• Note: Participants known to be BRAF V600 mutation-positive; prior therapy with BRAF±MEK inhibitor is at the treating investigator's discretion.

• For other tumor types: Must have a recurrent histologically or cytologically proven metastatic or locally advanced solid tumor, meeting each of the following:

‣ Tumor that is not amenable to curative treatment with surgery or radiation.

⁃ Tumor for which immune checkpoint inhibitors form part of standard-of-care therapy.

⁃ Participant has received at least one prior line of systemic anticancer therapy in the recurrent or metastatic setting.

• Has measurable disease per RECIST v1.1 as assessed by the local site investigator/radiology.